SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic tests and services for physicians treating patients with
cancer, announces it has received more than 50,000 COVID-19
specimens to date for processing through its RT-PCR technology at
its CLIA-certified, CAP-accredited high-complexity molecular
laboratory.
"We have continued to gain momentum in testing COVID-19
specimens while maintaining a standard of providing the vast
majority of COVID-19 test results to our healthcare provider
customers within 48 hours of receiving a sample," said Michael Nall, President and CEO of
Biocept. "I am proud of our team for working hard to scale
our business in a short time to handle this rapidly increasing
volume."
Biocept's growing list of clients for COVID-19 testing includes
hospitals, clinics, skilled nursing facilities, corporate clients
and athletic facilities.
Biocept is also reporting progress with its internally developed
COVID-19 specimen collection kits. The Company has received
verification from a contract research organization (CRO) of the
viricidal effects of the specimen collection tube used for shipping
patient samples. This was an important gating factor prior to
the adoption of the internally developed kits. The
Biocept-developed COVID-19 specimen collection kit will now be
validated as part of the Company's COVID-19 workflow in the
Company's lab prior to being sent to the U.S. Food and Drug
Administration (FDA) for Emergency Use Authorization (EAU)
review. Biocept remains on track for launching the
Biocept-developed specimen collection kits later this year for use
in its lab and for potential sales to other labs.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In
addition, Biocept recently added COVID-19 testing to support
efforts to fight the pandemic. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding the growth of demand for our COVID-19 testing
services, our ability to maintain and/or increase our COVID-19
testing capacity and provide timely results, the availability and
timing of delivery of specimen collection kits developed by
Biocept, and the ability of Biocept's platform to identify
cancer mutations and alterations to inform physicians about a
patient's disease and therapeutic options, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-provides-update-on-covid-19-testing-with-more-than-50-000-specimens-received-301146388.html
SOURCE Biocept, Inc.